Sponsored by:
Navigating an uncertain regulatory environment for mRNA-based products
The development of effective vaccines to combat COVID-19 has showcased the potential of mRNA technology, which is now under exploration for various clinical areas, including oncology, HIV, rare diseases, and personalized medicine.
Given that the application of mRNA technology is relatively new, regulatory guidelines and industry standards that address specific aspects of mRNA quality during process development are still evolving, with existing resources primarily focused on mRNA vaccines.
How this guidance will translate for developers of mRNA products for other therapeutic modalities remains to be seen. Developers will need to remain nimble during this period of evolution and stay aware of emerging regulatory guidelines applicable for their unique therapies. Collaborating with a strategic Contract Development and Manufacturing Organization (CDMO) partner that has the appropriate industry knowledge and experience can help developers navigate these challenges and bring novel mRNA products to market faster.
Specifically, the article covers the following topics:
- Current and developing regulatory guidance for mRNA products
- The importance of early engagement with regulatory bodies
- Choosing a strategic CDMO partner for mRNA development
